Insider trade

Officer sold ~$4.19M of JNJ shares in the open market

Traded Oct 17, 2025 · Filed Oct 20, 2025

Johnson & JohnsonJNJ

~$4.19M
Reported value · 22K sh @ $192.7072: 11K
Holds after · shares reported: +33.9%
stock since the trade · S&P 500 +15.0%, $193.22 → $258.66 on Oct 1

Why it stands out

Johnson & Johnson's Innovative Medicine, R&D sold $4.19M of Johnson & Johnson shares. Nobody planned it ahead of time.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Oct 17, 2025
Reporting period: Not applicable
Filed with the SEC: Oct 20, 2025

Officer$1M+

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$4,185,793

Shares × reported transaction price

Timing vs results

3 days after results of Oct 14, 2025, 96 days before results of Jan 21, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $193.22 on Oct 17, 2025, at its 52-week high, after an 8% rise over the previous 30 trading days

52-week range $142.06 (Jan 10, 2025) to $193.22 (Oct 17, 2025), 100% of the way up, from 250 adjusted closes. 30 trading days earlier: $178.43 on Sep 5, 2025. Describes the past only, not a forecast

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

FDA decision near the trade

FDA approved Darzalex Faspro on Nov 6, 2025, 20 days after this trade.

New use approved (efficacy supplement). Active ingredient: Daratumumab and Hyaluronidase-Fihj. From openFDA. Dates only; no link between the two is implied

After it was reported

After	Stock	S&P 500	Difference
7 days	-2.6%	+2.4%	-4.9%
30 days	+5.8%	-2.8%	+8.6%
90 days	+13.7%	+0.9%	+12.8%
180 days	+20.2%	+5.6%	+14.7%

Past results only. Not a forecast.

Source receipt

Record ID: 0000200406-25-000204
Filed / recorded: Oct 20, 2025, 11:13 PM UTC
Added to OQRO: Oct 2, 2026, 3:52 AM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: JOHNSON & JOHNSON
Issuer CIK: 200406
Ticker: JNJ
Reporting person: John C Reed
Relationship: Officer
Officer title: EVP, Innovative Medicine, R&D
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Oct 17, 2025
Transaction code: S
Shares / units: 21,721
Price per share: $192.7072
Acquired / disposed: Disposed (D)
Shares owned after: 10,658
Ownership form: Direct
Amendment: No

Footnotes from the filing

This transaction was executed in multiple trades at prices ranging from $192.69 to $192.87. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Around the same time

Major shareholder sold11mo ago

~$10KReported value · 1,000 sh @ $10.00

A big owner of Johnson & Johnson sold $10K of Johnson & Johnson shares. Nobody planned it ahead of time.

Why it stands out Official record

Major shareholder sold11mo ago

~$534KReported value · 52K sh @ $10.21

A big owner of Johnson & Johnson sold $534K of Johnson & Johnson shares. Nobody planned it ahead of time.

Why it stands out Official record

Major shareholder sold11mo ago

~$2KReported value · 200 sh @ $10.00

A big owner of Johnson & Johnson sold $2K of Johnson & Johnson shares. Nobody planned it ahead of time.

Why it stands out Official record